News Releases

CHP Canada Statement on the Role of Nicotine in COVID-19 Infection

Nicotine replacement therapies such as gums, patches, lozenges, and sprays are clinically proven to support smokers trying to break free from tobacco use. These products should not, however, be used to protect against COVID-19. Nicotine has not been tested against any strains of coronavirus and these products are not intended to prevent or treat COVID-19.

Consumer Health Products Canada (CHP Canada) advises Canadians who have questions on the COVID-19 pandemic and on how they can protect themselves from the virus, to rely on health professionals, public health officials, government-run health portals, and Health Canada-approved product labels for information. Products intended for medicinal use, such as Nicotine-Replacement Therapies (NRTs) for smoking cessation, should only be used for the purpose specified on the label or recommended by a qualified health professional.

Additionally, CHP Canada underlines that smoking has serious health consequences and that public health officials continue to see tobacco use as a risk factor for COVID-19 infection.

With respect to how they can reduce the overall risks of the COVID-19 pandemic, we remind all Canadians to rely on the recommendations of their local public health officials or the Public Health Agency of Canada.